Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
NASDAQ:CYTO
Price:
1.416 USD
-5.6%
Market Closed
Updated:
May 10, 2024
Altamira Therapeutics Ltd
Operating Income
|
Altamira Therapeutics Ltd
Operating Income Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Operating Income
-CHf5.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Operating Income
$16.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
4%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Operating Income
-$15.5m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Operating Income
CHf18.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Operating Income
$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Altamira Therapeutics Ltd's Operating Income?
Operating Income
-5.9m
CHF
-5.9m
CHF
Based on the financial report for Dec 31, 2023, Altamira Therapeutics Ltd's Operating Income amounts to -5.9m CHF.
What is Altamira Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
12%
12%
Over the last year, the Operating Income growth was 54%. The average annual Operating Income growth rates for Altamira Therapeutics Ltd have been -4% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
